



COVID-19 VACCINE UPDATES

February 28, 2023

Before We Start

- All participants will be muted for the presentation.
- You may ask questions using the Q&A box, and questions will be answered at the end of the presentation.
- Continuing education is available for nurses, medical assistants, and pharmacists/pharmacy techs attending the webinar or watching the recording. If you're watching in a group setting and wish to claim CE credit, please make sure you register for the webinar and complete the evaluation as an individual.
- You can find more information on our [Web Page](#).

Learning Objectives

- Discuss current COVID-19 vaccine recommendations
- Describe national advisory committee meetings about the vaccine schedule and vaccine presentations
- Identify recent storage and handling issues, and strategies to prevent these issues
- Discuss vaccine ordering and distribution updates

Presenters from WA DOH

Heidi Kelly, MSHS, RN-BC
Public Health Nurse Consultant

Shanae Wischnesky
COVID-19 Provider Support Specialist Supervisor

Ariel VanZandt
COVID-19 Vaccine Ordering and Distribution Specialist

Continuing Education

- This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. Upon successful completion of this activity, 1.0 contact hours will be awarded.
- This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.0 administrative continuing education unit.
- This knowledge activity was approved by the Washington State Pharmacy Association for 1.0 contact hours. The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.



Disclosures

The planners and speaker of this activity have no relevant financial relationships with any commercial interests pertaining to this activity.

COVID-19 Vaccine Clinical Update

HEIDI KELLY, MSHS, RN-BC

Outline

- EVUSHELD™ no longer authorized
- Review of current COVID-19 Vaccination Schedules
- ACIP Meeting Highlights

EVUSHELD™

FDA announces Evusheld is not currently authorized for emergency use in the U.S.

Share Tweet LinkedIn Email Print

Drug Safety and Availability

Information about
Nitrosamine Impurities in
Medications

Medication Guides

Drug Safety Communications

Food and Drug Administration
Overdose Prevention
Framework

Drug Shortages

FDA Drug Safety Podcasts

FDA announces Evusheld is not currently authorized for emergency use in the U.S.

Update [1/26/2023] The U.S. Food and Drug Administration today revised the [Emergency Use Authorization](#) (EUA) for Evusheld (tixagevimab co-packaged with cilgavimab) to limit its use to when the combined frequency of non-susceptible SARS-CoV-2 variants nationally is less than or equal to 90%. Based on this revision, **Evusheld is not currently authorized for use in the U.S. until further notice by the Agency.**

Data show Evusheld is [unlikely to be active](#) against certain SARS-CoV-2 variants. According to the most recent CDC [Nowcast data](#), these variants are projected to be responsible for more than 90% of current infections in the U.S. This means that Evusheld is not expected to provide protection against developing COVID-19 if exposed to those variants.

Today's action to limit the use of Evusheld prevents exposing patients to possible side effects of Evusheld such as allergic reactions, which can be potentially serious, at a time

Content current as of:
01/26/2023

Regulated Product(s)
Drugs

Topic(s)
Safety - Issues, Errors, and
Problems


Source: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us>




Review of Current COVID-19 Vaccine Schedules

COVID-19 Vaccination Schedule Infographic for People who are NOT Moderately or Severely Immunocompromised


People ages 6 months through 4 years




People age 5 years



People ages 6 through 11 years



People ages 12 years and older



People ages 18 years and older who previously received Janssen primary series dose‡



SOURCE: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines>

COVID-19 Vaccination Schedule Infographic for People who ARE Moderately or Severely Immunocompromised


People ages 6 months through 4 years



People age 5 years




People ages 6 through 11 years



People ages 12 years and older



People ages 18 years and older who previously received Janssen primary series dose*



SOURCE:
<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines>

6mos-4-Year-Old COVID-19 Vaccine Points to Consider

- Mixed product for primary series is not recommended.
- Children who received 2 primary Pfizer doses should receive a bivalent Pfizer for their 3rd dose.
- Children who received 2 Moderna doses are authorized to receive Moderna Bivalent as a booster dose (3rd dose).
- Children who received a mixed 3-dose primary series with any combination of Moderna and Pfizer vaccines cannot receive any booster dose until age 5 years.

SOURCE: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#covid-vaccines>

Children 5-Year-Old COVID-19 Vaccine Points to Consider

- Children 5 years who received 2 Moderna primary doses are recommended to receive Pfizer or Moderna bivalent for a booster dose.
- Children 5 years who received 2 Pfizer doses are recommended to receive a bivalent Pfizer dose for their booster.
- Mixed product for primary series is not recommended.

ACIP Meeting Highlights



Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™

Vaccines site ▾🔍

Advisory Committee on Immunization Practices (ACIP)



COVID-19 Vaccination Recommendations


[ACIP Recommendations](#)

[Clinical Considerations for Use of COVID-19 Vaccines](#)

Source: <https://www.cdc.gov/vaccines/acip/index.html>

Trends in weighted variant proportion estimates & Nowcast

United States, November 6, 2022-February 11, 2023




PI=Prediction Interval, VOC=Variants of Concern, VBM=Variants Being Monitored, <https://covid.cdc.gov/covid-data-tracker/#variant-proportions> Accessed Jan 20, 2023

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

Estimated Number of Reported COVID-19 Cases by Variant

Variant Proportions Scaled by Positive Nucleic Acid Amplification Test (NAAT) Counts




CDC COVID-19 Lab Coordinating Unit Strain Surveillance and Emerging Variant Group. Data sources: <https://covid.cdc.gov/covid-data-tracker/#variant-proportions> and https://covid.cdc.gov/covid-data-tracker/#trends_newtestresultsreported_7daytestingpositive_00

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

Nowcast Estimates of Variant Proportions by HHS Region

United States, January 15-21, 2023




HHS=Health and Human Services

<https://covid.cdc.gov/covid-data-tracker/#variant-proportions> Accessed Jan 20, 2023

SOURCE: Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting Presentation- COVID-19 Update on Current Epidemiology of the Pandemic and SARS-CoV-2 Variants (fda.gov)


Weekly population-based rates of COVID-19-associated hospitalizations by age group— COVID-NET, March 2020–February 2023



Gray boxes indicate potential reporting delays. Interpretation of trends should be excluded from these weeks.

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

Monthly Age-Adjusted Rates of Lab-Confirmed Hospitalizations by Vaccination Status among Adults Ages ≥18 Years — COVID-NET, January 2021–December 2022



Data are based on all hospitalizations regardless of reason for admission. **Unvaccinated:** No recorded doses of COVID-19 vaccine. **Primary series ± ≥1 booster:** Completed a primary series with or without ≥1 booster dose but did not receive an updated bivalent booster dose. **Vaccinated, but no bivalent booster:** Completed a primary series with or without ≥1 booster dose but did not receive an updated bivalent booster dose. **Updated bivalent booster:** Received updated bivalent booster dose. Persons with partial or unknown vaccination status are excluded. See <https://covid.cdc.gov/covid-data-tracker/#covidnet-hospitalizations-vaccination> for complete definitions of vaccination categories.

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

U.S. COVID-19 Vaccination Coverage (%) of Total Population by Age Group — February 8, 2023

Coverage / Age (years)	<2	2-4	5-11	12-17	18-24	24-49	50-64	≥65
At least 1-dose [†]	7.6	10.3	39.7	71.9	81.9	85.2	95.0	95.0
Completed primary series	3.7	5.5	32.6	61.6	66.5	72.0	83.7	94.2
1st monovalent booster*	-	-	3.3	16.6	27.2		45.3	64.6
2nd monovalent booster *	-	-	-	-	-	-	10.6	25.3
Bivalent booster**	0.2	0.3	4.0	7.0	6.7	11.2	20.3	40.8
Unvaccinated	92.4	89.7	60.3	28.1	18.1	14.8	— [†]	— [†]

* Monovalent booster dose coverage as of August 26, 2022

** Bivalent booster coverage is independent of 1st and 2nd dose monovalent coverage

[†]Note: Coverage is capped at 95%

Source: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends> Updated February 10, 2023

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

American Academy of Pediatrics

Recommends coronavirus disease 2019 (COVID-19) vaccination for all infants, children, and adolescents 6 months of age and older who do not have contraindications to receiving a COVID-19 vaccine authorized or approved for use for their age. This includes primary series and/or booster doses as recommended by the CDC.



SOURCE: <https://publications.aap.org/pediatrics/article/150/3/e2022058700/188297/COVID-19-Vaccines-in-Infants-Children-and>

COVID-19 vaccine

Where we are now

- Current COVID-19 vaccine recommendations are **complex**
- Uptake of current bivalent vaccine is **low**
- SARS-CoV-2 continues to evolve, but recent virus evolution has not led to large population-level surges in cases or hospitalizations
- Most adults have a prior infection, prior vaccination, or both
- Hospitalization rates are highest **older adults**, but remain **low** among people who have received a **bivalent booster**


SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

Question for consideration

- Does ACIP support **harmonizing** the vaccine strain composition for mRNA COVID-19 vaccines across both primary series and booster doses:
Changing the primary series from monovalent (Original) to bivalent (Original plus Omicron BA.4/5) for all ages?

Current recommendations (Simplified representation)

People ages 6 months and older*




*Ages and vaccines as authorized by FDA and recommended by ACIP/CDC

For children ages 6 months-4 years of age who start a Pfizer-BioNTech primary series, the third dose in a 3-dose primary series is a bivalent dose

Future proposed recommendations

People ages 6 months and older*



*Ages and vaccines as authorized by FDA and recommended by ACIP/CDC

For children ages 6 months-4 years of age who start a Pfizer-BioNTech primary series, 3-dose primary series still needed

45

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-08-Oliver-508.pdf>

Possible number of mRNA COVID-19 vaccine products with a bivalent primary series

Moderna: 2 products



Pfizer-BioNTech: 3 products



**Could be reduced to
5 total products**

**Would eliminate look-alike vials for
Moderna and Pfizer-BioNTech**

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-08-Oliver-508.pdf>

How frequently should people get a COVID-19 vaccine?

Summary

- Winter months and immune escape variants have impacted COVID-19 epidemiology
 - This past winter did not see same level of increases in cases/hospitalizations as previous winters
- Time since last COVID-19 vaccine dose may both increase the incremental benefits of a COVID-19 vaccine, and decrease the risk of myocarditis
- Vaccine protection likely declines over time
- A plan for a **fall booster dose** could provide added protection, at a time when many would be ~1 year from last dose
 - Future epidemiology and SARS-CoV-2 virus evolution could help determine the need for continued annual boosters

SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-10-Oliver-508.pdf>

Policy considerations for bivalent primary series

- Policy on bivalent primary series will be coordinated with **FDA** for regulatory action, and **CDC/ACIP** for recommendations for use



SOURCE: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-24/COVID-08-Oliver-508.pdf>


Knowledge Check One

Joe brings their 3 y/o in for a COVID-19 bivalent booster dose. Their last dose was in October. The child received two Moderna and one Pfizer monovalent dose for their primary series. What is the best course of care for this client?

- A. Explain to Joe that their child is not currently eligible for a bivalent booster dose at this time.
- B. Offer the child a Moderna Bivalent dose since it was the last product they received.
- C. Offer the child a Pfizer Bivalent dose because it is safer for 3 year olds.

Knowledge Check One Answer

A: Explain to Joe that their child is not currently eligible for a bivalent booster dose at this time.

Children ages 6 months–4 years who received 1 monovalent Moderna vaccine and 1 monovalent Pfizer-BioNTech vaccine for the first 2 doses of a primary series should follow a [3-dose schedule](#) . A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the 3-dose primary series. Currently, children in this age group who receive a mixed 3-dose primary series with any combination of Moderna and Pfizer-BioNTech vaccines cannot receive any booster dose until age 5 years (see [Appendix D](#)).

[SOURCE: Clinical Guidance for COVID-19 Vaccination | CDC](#)

Knowledge Check Two

Juno is a 5 y/o who received 2 doses of monovalent Pfizer COVID-19 vaccine. Their last dose was in November. They are in for their bivalent booster dose. What is the best course of care for this child?

- A. Explain to parent child is not eligible for booster dose at this time, they need to wait at least 6 months before receiving a booster dose.
- B. Prepare and administer a Pfizer Bivalent booster dose.
- C. Juno is eligible for a bivalent booster dose of Moderna or Pfizer at this time.

Knowledge Check Two Answer

B: Prepare and administer a Pfizer Bivalent booster dose.

Children age 5 years: A 2-dose primary series and 1 bivalent Pfizer-BioNTech booster dose is recommended. The primary series doses are separated by 3–8 weeks and the bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who complete a Pfizer-BioNTech primary series.

[SOURCE: Clinical Guidance for COVID-19 Vaccination | CDC](#)

Knowledge Check Three

A 65 year old diabetic arrived to the clinic with a request for a COVID-19 Bivalent Booster dose. Their last bivalent dose was in October 2022. What is the best course of care for this client?

A: Prepare and administer the bivalent vaccine, as requested and offer the Influenza vaccine as well.

B: Explain to the client that they are not currently authorized for an additional bivalent dose since they have already received one. Offer an Influenza vaccine if they are in need of one as well.

C: Give another monovalent dose, since they can't get anymore bivalent doses.

Knowledge Check Three Answer

B: Explain to the client that they are not currently authorized for an additional bivalent dose since they have already received one. Offer an Influenza vaccine if they are in need of one as well.

People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s) with the following exception: children 6 months–4 years who receive a 3-dose Pfizer-BioNTech primary series are not authorized to receive a booster dose at this time regardless of which Pfizer-BioNTech vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose. Monovalent mRNA vaccines are not authorized as a booster dose.

[SOURCE: Clinical Guidance for COVID-19 Vaccination | CDC](#)

VAERS is the nation's early warning system for vaccine safety



VAERS

Vaccine Adverse Event
Reporting System

<http://vaers.hhs.gov>



Source: T Shimabukuro, Advisory Committee on Immunization Practices presentation; 04/20/2022 meeting. Available at [ACIP April 20, 2022 Presentation Slides](#) | [Immunization Practices](#) | [CDC](#)

Promoting v-safe in practice – Vaccinators, we need your help!

How:

- Provide the **v-safe** information sheet to patients
 - Ideally this should occur prior to vaccination for young children
- Display posters of **v-safe**
- Direct patients to vsafe.cdc.gov to enroll

<https://www.cdc.gov/coronavirus/2019ncov/vaccines/safety/vsafe/printresources.html>





**Get vaccinated.
Get your smartphone.
Get started with v-safe.**

What is v-safe?

V-safe provides personalized and confidential health check-ins via text messages and web surveys so you can quickly and easily share with CDC how you or your dependent feel after getting a COVID-19 vaccine. It takes just a few minutes to enroll and your participation in **v-safe** helps us monitor the safety of COVID-19 vaccines for everyone.

V-safe features:

- **Enroll your dependents** and complete check-ins on their behalf
- **Enter and report** how you feel after **first, second, additional, and booster doses**

How can I enroll and how does it work?

You can enroll in **v-safe** after any dose of COVID-19 vaccine by using your smartphone and going to vsafe.cdc.gov.

During the first week after each vaccination, **v-safe** will send you a text message each day to ask how you are feeling. After that, you will receive occasional check-ins, which you can opt out of at any time. Depending on your answers, someone from CDC may call to get more information. Your personal information in **v-safe** is protected so it's safe and private*.

How can I enroll my dependent?

You can enroll any family member (or friend) who is eligible to be vaccinated in **v-safe**. Children under 16 years old must be enrolled using a parent or guardian's **v-safe** account. You can add a dependent to your existing account or create a new account if you don't have one yet. Creating an account to enroll a dependent does not require that you enter your own vaccination information or complete health check-ins for yourself.

Need step-by-step instructions? Go to: www.cdc.gov/vsafe



v-safe™
after vaccination
health checker

Sign up with your
smartphone's browser
at vsafe.cdc.gov

Share with your friends
and CDC that you are
using v-safe! Post
a selfie and use the
hashtag #BeSafeVSafe



Need help with v-safe?
Call 800-CDC-INFO (800-232-4636)
TTY 888-232-6348
Open 24 hours, 7 days a week
Visit www.cdc.gov/vsafe

*v-safe uses existing information systems managed by CDC, FDA, and other federal agencies. These systems use strict security measures to keep information confidential. These measures comply, where applicable, with the following federal laws, including the Privacy Act of 1974, standards enacted that are consistent with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the Federal Information Security Management Act, and the Freedom of Information Act.



C532K195-A 12/22/2021

COVID-19 Vaccine Storage and Handling

SHANAE WISCHNESKY

Digital Data Loggers

- Ensure that the digital data logger (DDL) is being used to the manufacturer's specifications
 - Follow manufacturer guidelines for placement of the display and probe
 - Ensure all components of DDL are working and operational
 - Have a current valid certificate of calibration
 - Set DDL to record temperature at least every 30 minutes
- Have a backup DDL for emergencies and vaccine transfers
 - This should meet all the same requirements as the primary DDL




Temperature Log Formats

- **Approved Temp Log Formats**
 - COVID-19 Vaccine Temp Log
 - Childhood Vaccine Program (CVP) Temp Log
 - DDL Summary Reports
- **Unapproved Temp Log Formats**
 - Excel workbooks with only date and temp
 - Handwritten logs

Approved DDL Summary Report

Company Name: [REDACTED]
Company Address: [REDACTED]
Node Selected: PHARMACY Location: PHARMACY
Start Date: 12/04/2020 11:38 End Date: 12/10/2020 11:38
Number of Samples: 574
Created By: [REDACTED] DateTime: 12/11/2020 7:38:50 PM (UTC)




InTemp

Report [REDACTED] - No Alarm

Report Created By
Name: [REDACTED] Account: [REDACTED]
Email: [REDACTED]

Report Information
Report Date: 02/24/2021 00:53:36 PST Configured Date: 02/23/2021 00:01:24 PST
Deployment Name: SVH - 21002319 Download Date: 02/24/2021 00:01:02 PST
Logger Model: CX402 Logging Interval: 5m
Serial Number: [REDACTED] Total Data Points: 288


Temperature Alarm Information
High Alarm Triggered: NO Number of High Alarms: 0
Low Alarm Triggered: NO Number of Low Alarms: 0
High Alarm Limit: 5.00 Number of Probe Disconnects: 0
Low Alarm Limit: -10.00 Elapsed Time Outside Alarm Limits: 0
Duration: Alarm after 15m Cumulative Elapsed Time Probe Disconnected: 0



Approved Paper Temperature Log

COVID-19 Vaccine

Temperature Log for Refrigerator Vaccine Storage (Fahrenheit) Days 1-15



Store COVID-19 vaccines between 36°F and 46°F. Using a digital data logger (DDL), check and record the temperature daily using one of the options below. Save this record for 3 years, unless your state/local jurisdiction requires a longer time period. See CDC's *Vaccine Storage and Handling Toolkit*, *COVID-19 Addendum*, for additional information.

Option 1: Minimum/Maximum (Min/Max) Temperatures (preferred)

- Most DDLs display minimum and maximum temperatures. Check and record the min/max temperatures at the start of each workday.
- Document these temperatures in the min/max temperature row under the appropriate date.

Option 2: Current Temperature

- If the DDL does not display min/max temperatures, check and record the current temperature at the start and end of the workday.
- Document these temperatures by writing an "X" in the row that corresponds to the refrigerator temperature under the appropriate day of the month.
- Review the continuous DDL temperature data daily.

! If the temperature is out of range, TAKE ACTION!

- Do **NOT** discard the vaccine.
- Label the vaccine **"Do Not Use."**
- Complete the Vaccine Troubleshooting Record.
- Contact the manufacturer to determine under what conditions (refrigerated) to store the vaccine as quickly as possible.

Month _____ PIN Number _____


Facility Name _____

OPT ION 1	Day of the month	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
	Time															
	Staff initials															
	Min/max temperatures															
Temperatures lower than 36°F and higher than 46°F are out of range. Complete a Vaccine Troubleshooting Record. Contact the manufacturer and your immunization program.																
OPT ION 2	Time	AM	PM	AM	PM	AM	PM	AM	PM	AM	PM	AM	PM	AM	PM	AM
	Staff initials															
	36°F															
	37°F															
	38°F															
	39°F															
	40°F															
	41°F															
	42°F															
	43°F															
	44°F															
45°F																
46°F																

For additional information, see the vaccine manufacturer's product information. Adapted with appreciation from the Immunization Action Coalition (IAC) temperature log

01/07/2021 CS3216294

Approved CVP Log

REFRIGERATOR TEMPERATURE MONITORING LOG: Days 1-15																					
CLINIC NAME: _____										PROVIDER PIN: _____					F° / C°						
FRIDGE NAME/NUMBER: _____										MONTH/YEAR: _____											
RECORDING TEMPERATURES: 1. Circle if you are recording in C° or F° on the temperature log. 2. Record min/max temps preferably at the start of clinic hours. 3. Record storage unit temperatures twice a day. 4. Place an "X" or record the temperature in the box that corresponds with the temperature range.										IF A TEMPERATURE RECORDING IS IN THE SHADED ZONE: 1. Store the vaccine under proper conditions as quickly as possible. Place the affected vaccine in a bag and mark the vaccine as "Do not use." 2. Call the vaccine manufacturers to determine whether the vaccines are viable. 3. Contact your local health jurisdiction for further assistance: _____ 4. Use the Changes tracking area to record the actions taken to correct the problem.											
Notes	Day of Month	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15					
	Min/Max Temp																				
	Refrigerator																				
	Exact Time of Temp	am	pm	am	pm	am	pm	am	pm	am	pm	am	pm	am	pm	am	pm				
	Room Temp																				
Staff Initials																					
Refrigerator Temperature	49°F (9.5°C)	<div style="text-align: center;"> DANGER!!! WARNING TOO WARM Call your Local Health Department WARNING TOO WARM </div>																			
	48°F (8.9°C)																				
	47°F (8.4°C)																				
	46°F (7.8°C)																				
	45°F (7.3°C)																				
	44°F (6.8°C)																				
	43°F (6.2°C)																				
	42°F (5.5°C)																				
	41°F (5.0°C)																				
	40°F (4.5°C)																				
	39°F (3.9°C)																				
	38°F (3.4°C)																				
	37°F (2.7°C)																				
	36°F (2.3°C)																				
	35°F (1.7°C)																				
34°F (1.1°C)	<div style="text-align: center;"> DANGER!!! WARNING TOO COLD Call your Local Health Department WARNING TOO COLD </div>																				
33°F (0.6°C)																					
32°F (0.0°C)																					
Changes	Please list any steps you've taken to address temperature or storage unit issues	DATE 1/1	°F / °C 33.1 °F	Action Taken: Fridge control adjusted, called UH, etc.																	

Unapproved Excel spreadsheets

Nodeid	NodeName	Location	Node Type	DataTimeSta	Unit	DataValue
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 12:14:10 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 12:23:10 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 12:44:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 12:53:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 1:14:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 1:29:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 1:44:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 1:53:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 2:14:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 2:23:10 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 2:44:10 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 2:53:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 3:14:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 3:23:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 3:44:09 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 3:53:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 4:14:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 4:23:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 4:44:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 4:53:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 5:14:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 5:23:08 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 5:44:07 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 5:53:07 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 6:14:07 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 6:23:07 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 6:44:14 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 6:53:14 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 7:14:14 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 7:23:13 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 7:44:13 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 7:53:13 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 8:14:13 AM	C
170665	LAB1045_Vacc	1	COATING	Temperature	1/28/2022 8:23:12 AM	C

Unapproved Handwritten Log

FREEZER TEMPERATURE LOG
TEMPERATURE MUST MAINTAIN BETWEEN
-50 AND -15 DEGREES CELSIUS
-58 AND +5 DEGREES FAHRENHEIT

JANUARY '23 (FREEZER)

Date	AM Temperature	PM Temperature
1		
2		
3 01-03-23	-26.1	-27.2
4 01-04-23	-26.6	-26.6
5 01-05-23	-26.2	-28.2
6 01-06-23	-29.1	
7		
8		
9		
10 01-10-23	-28.0	-27.2
11 01-11-23	-27.5	-28.6
12 01-12-23	-26.7	-28.5
13 01-13-23	-25.6	-26.1
14		
15		
16		
17 01-17-23	-27.7	-27.1
18 01-18-23	-26.0	-27.5
19 01-19-23	-26.3	-27.1
20 01-20-23	-26.7	-25.5
21		
22		
23 01-23-23	-27.6	-28.6
24 01-24-23	-25.6	-28.4
25 01-25-23	-28.8	-28.5
26 01-26-23	-27.6	-27.6
27 01-27-23	-26.8	-28.4
28 01-28-23	-27.2	-28.4
29		
30		
31		

If for any reason the temperature is not within parameter notify supervisor immediately.

Storage and Handling Incidents

- Ensure that temperature excursions are addressed
 - When submitting temperature log for the month:
 - Ensure all fields about excursions are filled out
 - Fill out notes section on actions taken to resolve the excursion (e.g. manufacturer case number)
 - Notify DOH by emailing COVID.vaccine@doh.wa.gov

The screenshot shows a web form for reporting storage and handling incidents. The form is divided into several sections, some of which are highlighted with yellow boxes. The first section asks if the unit was used to store any COVID-19 vaccine in the past month, with radio buttons for 'Yes' (selected) and 'No'. The second section, highlighted with a yellow box, contains four questions with radio buttons for 'Yes' and 'No': 'Was there a temperature excursion during this month for this unit?', 'Was the manufacturer contacted?', 'Was DOH notified?', and 'Was the vaccine deemed viable?'. The third section, also highlighted with a yellow box, is for uploading files, including 'Upload File for Storage 1' and 'Additional Upload File for Storage 1 (if needed)'. The fourth section, highlighted with a yellow box, is for 'Excursion Detail', where users can provide details about the excursion. The final section asks if the user needs to update their storage units and if there is anything else to share. The form ends with 'Submit' and 'Save & Return Later' buttons.

Have you used this unit during the past month to store any COVID-19 vaccine? ☒ Yes ☐ No ☐ No, but storing COVID-19 vaccine in new unit [reset](#)

* must provide value

	Yes	No	
Was there a temperature excursion during this month for this unit?	<input checked="" type="radio"/>	<input type="radio"/>	reset
Was the manufacturer contacted?	<input type="radio"/>	<input type="radio"/>	reset
Was DOH notified?	<input type="radio"/>	<input type="radio"/>	reset
Was the vaccine deemed viable?	<input type="radio"/>	<input type="radio"/>	reset

Upload File for Storage 1 [Sensor History Report Sept \(1\).pdf \(0.48 MB\)](#)
* must provide value [Upload new version](#) or [Remove file](#)

Additional Upload File for Storage 1 (if needed) [Upload file](#)

Excursion Detail. Please include details around your excursion such as the type of vaccine affected, the manufacturer recommendations and/or case number. If no details are included, provider support staff will need to reach out to gather more information on the excursion.
* must provide value
[Expand](#)

Do you need to update your storage units on your provider agreement? If Yes, someone from the Provider Support Team will reach out to you. ☒ Yes ☐ No [reset](#)

* must provide value

Is there anything else you would like to share?
[Expand](#)

[Submit](#)
[Save & Return Later](#)

Resources

- CDC Storage and Handling Toolkit

<https://doh.wa.gov/emergencies/covid-19/healthcare-providers/vaccine-information-healthcare-providers/management>

- COVID-19 Vaccine Management Page

<https://doh.wa.gov/emergencies/covid-19/healthcare-providers/vaccine-information-healthcare-providers/management>

- Storage and Handling of Pfizer-BioNTech COVID-19 Vaccines

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/storage.html>

- Storage and Handling of Moderna COVID-19 Vaccines

<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage.html>

- Send an email to COVID.Vaccine@doh.wa.gov for questions

COVID-19 Vaccine Ordering and Distribution

ARIEL VANZANDT

Current Adult COVID-19 Vaccine Products Available

- **Monovalent**
 - Moderna Red Cap (100 dose minimum), 12+ years
 - Pfizer Comirnaty, Grey Cap (180 dose minimum), 12+ years
 - Novavax (100 dose minimum), 12+ years
- **Bivalent**
 - Moderna Blue Cap (100 dose minimum), 12+ years
 - Pfizer Grey Cap (180 dose minimum), 12+ years
 - Pfizer Single Dose Vials, Grey Cap (50 dose minimum, 150 maximum), 12+ years

Current Pediatric COVID-19 Vaccine Products Available

- **Monovalent**
 - Moderna Blue Cap (100 dose minimum), 6mos-5 years
 - Moderna Blue Cap (100 dose minimum), 6-11 years
 - Pfizer Maroon Cap (100 dose minimum), 6mos-4 years
 - Pfizer Orange Cap (100 dose minimum), 5-11 years
- **Bivalent**
 - Moderna Pink Cap (100 dose minimum), 6mos-5 years
 - Moderna Blue Cap (100 dose minimum), 6-11 years
 - Pfizer Maroon Cap (100 dose minimum), 6mos-4 years
 - Pfizer Orange Cap (100 dose minimum), 5-11 years

Requesting Fewer Doses

- Providers can request fewer than the minimum order amount by requesting doses from another provider.
- Doses available for transfer can be viewed in the WAIS on the [Vaccine Advertisement Page](#).
- If you have doses listed for transfer, please ensure you have the product name typed into the “Comments” field.

Opting Out of Ancillary Kits

Please note: The opt-out option is not currently available for Pfizer pediatric COVID-19 vaccine as Pfizer pediatric ancillary kits contain the diluent necessary to administer the vaccine.

Create Order

Organization: KAIA'S ORGANIZATION
Facility: ANGEL'S CLINIC
Phone Number:
Phone Extension:
Email:

First Name:
Middle Name:
Last Name:
Address: 222 10TH ST
City: AMANDA PARK
State: WA
Zip: 98526

Monday: ☐ 09:00 12:00 13:00 17:00
Wednesday: ☐ 09:00 12:00 13:00 17:00
Friday: ☐ 09:00 12:00 13:00 17:00

Tuesday: ☐ 09:00 12:00 13:00 17:00
Thursday: ☐ 09:00 12:00 13:00 17:00

PIN:
Order Date: 01/27/2022
Submitter: MONICA MAESE (MAESEM)
Comments:

Instructions:
Order Status: In Progress

Inventory Last Submitted:
Vaccine Administered Report Last Submitted: N/A
Please Submit your Monthly Vaccine Administered Report before reconciling your vaccines.
Last Order Submitted: 01/06/2022 08:21:22 AM

Inventory Transaction Report Lot Number Summary Edit Temperature Doses Administered Report

Order Frequency: Order Timing:
Order Schedule:

Order Details

Vaccine	Vaccine Name	Funding Source	Dose Used Last Month	Physical Inventory	Order Quantity	Urgent	Priority Reason	Comments
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	Pfizer COVID-19-1170 mRNA 30mcg/0.3mL	PAN	0	0				
COVID-19, mRNA, LNP-S, PF, 100 mcg/ 0.5 mL dose	Moderna COVID-19 mRNA 100mcg/0.5mL	PAN	0	0	300	<input type="checkbox"/>	--select--	Opt out of ancillary kit

Expiration Dates

- Pfizer
 - Pfizer received shelf-life extensions of all TRIS products (12+ years)
 - [Pfizer-BioNTech COVID-19 Lot Expiry \(covidvaccine.com\)](https://covidvaccine.com)
- Moderna
 - Moderna received extensions on monovalent products (adult and pediatric)
 - [Moderna \(modernacovid19global.com\)](https://modernacovid19global.com)

Inventory Management

As products continue to expire and retire, please ensure your inventories are up to date in the WAIS and VaccineFinder.

- WAIS Inventory Management
 - [Updating Inventory](#)
 - [Documenting Wastage](#)
- VaccineFinder Inventory Management
 - [Inventory Assistance](#)

Commercialization and the Future of Monovalent Vaccines

- No concrete details yet.
- We expect commercialization to happen early fall/late summer 2023.
- Additional details will be released as we learn more from CDC.
- Details will be shared via email, during monthly partner calls, and via the biweekly COVID newsletter.
- ACIP had extensive discussions about the future of Monovalent products the week of February 20. No official guidance nor decisions have been made.

Obtaining Continuing Education

- Continuing education is available for nurses, medical assistants, pharmacists and pharmacy technicians
 - There is no cost for CEs
- Expiration date is May 28, 2023
- Successful completion of this continuing education activity includes the following:
 - Attending the entire live webinar or watching the webinar recording
 - Completing the evaluation after the live webinar (will be sent by email March 1) or webinar recording
 - **On the evaluation, please specify which type of continuing education you wish to obtain**
- **Please note:** CE certificates are NOT generated after evaluation completion—CE certificates will be sent by DOH via email within a few weeks after evaluation completion
- If you have any questions about CEs, contact Trang Kuss at trang.kuss@doh.wa.gov

Questions?





To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.